HOOKIPA Pharma Inc banner

HOOKIPA Pharma Inc
NASDAQ:HOOK

Watchlist Manager
HOOKIPA Pharma Inc Logo
HOOKIPA Pharma Inc
NASDAQ:HOOK
Watchlist
Price: 1.02 USD -2.86% Market Closed
Market Cap: $12.6m

During the last 3 months HOOKIPA Pharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 15% over this period (open performance analysis).

The last transaction was made on Aug 19, 2025 by Peters Malte , who sold 20.7k USD worth of HOOK shares.

Last Transactions:
Peters Malte
$-20.7k
Coelho Mary Theresa
$-12.5k
Peters Malte
$-26.8k
Kandera Reinhard
$+507.5
Kandera Reinhard
$+571.2
Aldag Jorn
$+414.2
Aldag Jorn
$+405
Aldag Jorn
$+445
Aldag Jorn
$+445.6
Kandera Reinhard
$+1.1k
Matushansky Igor
$-1.3k
Sofinnova Capital Vi Fcpr
$-381.2k
Sofinnova Capital Vi Fcpr
$-50.4k
Sofinnova Capital Vi Fcpr
$-48.2k
Sofinnova Capital Vi Fcpr
$-37.5k
Sofinnova Capital Vi Fcpr
$-72.2k
Sofinnova Capital Vi Fcpr
$-55.6k
Sofinnova Capital Vi Fcpr
$-58.9k
Sofinnova Capital Vi Fcpr
$-242.8k
Matushansky Igor
$-13.5k
Matushansky Igor
$-444.6
Sofinnova Capital Vi Fcpr
$-300
Sofinnova Capital Vi Fcpr
$-40.3k
Sofinnova Capital Vi Fcpr
$-14.9k
Sofinnova Capital Vi Fcpr
$-3.9k
Sofinnova Capital Vi Fcpr
$-3.9k
Matushansky Igor
$-7k
Lilja Anders
$-5k
Orlinger Klaus
$-8.2k
Orlinger Klaus
$-2k
Orlinger Klaus
$-9.6k
Matushansky Igor
$-10.3k
View All Transactions

During the last 3 months HOOKIPA Pharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 15% over this period (open performance analysis).

The last transaction was made on Aug 19, 2025 by Peters Malte , who sold 20.7k USD worth of HOOK shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
60k USD
2
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

HOOKIPA Pharma Inc
Insider Trading Chart

HOOKIPA Pharma Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

HOOKIPA Pharma Inc
Last Insider Transactions

Global
Insiders Monitor

HOOKIPA Pharma Inc
Glance View

Market Cap
12.6m USD
Industry
Biotechnology

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.

HOOK Intrinsic Value
1.4 USD
Undervaluation 27%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett